NO20006021D0 - Fremgangsmåte for fremstilling av jern-dekstran forbindelse - Google Patents

Fremgangsmåte for fremstilling av jern-dekstran forbindelse

Info

Publication number
NO20006021D0
NO20006021D0 NO20006021A NO20006021A NO20006021D0 NO 20006021 D0 NO20006021 D0 NO 20006021D0 NO 20006021 A NO20006021 A NO 20006021A NO 20006021 A NO20006021 A NO 20006021A NO 20006021 D0 NO20006021 D0 NO 20006021D0
Authority
NO
Norway
Prior art keywords
iron
preparation
dextran compound
dextran
compound
Prior art date
Application number
NO20006021A
Other languages
English (en)
Norwegian (no)
Other versions
NO20006021L (no
Inventor
Hans Berg Andreasen
Lars Christensen
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of NO20006021L publication Critical patent/NO20006021L/no
Publication of NO20006021D0 publication Critical patent/NO20006021D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
NO20006021A 1998-11-20 2000-11-28 Fremgangsmåte for fremstilling av jern-dekstran forbindelse NO20006021D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199801526A DK173138B1 (da) 1998-11-20 1998-11-20 Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
PCT/DK1999/000425 WO2000030657A1 (en) 1998-11-20 1999-07-29 A process for producing an iron-dextran compound

Publications (2)

Publication Number Publication Date
NO20006021L NO20006021L (no) 2000-11-28
NO20006021D0 true NO20006021D0 (no) 2000-11-28

Family

ID=8105751

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006021A NO20006021D0 (no) 1998-11-20 2000-11-28 Fremgangsmåte for fremstilling av jern-dekstran forbindelse

Country Status (26)

Country Link
US (2) US6977249B1 (id)
EP (1) EP1123103B1 (id)
JP (1) JP2002530345A (id)
KR (1) KR20010071767A (id)
CN (1) CN1308539A (id)
AR (1) AR019403A1 (id)
AT (1) ATE225180T1 (id)
AU (1) AU756555B2 (id)
BR (1) BR9910834A (id)
CA (1) CA2332882A1 (id)
DE (1) DE69903329T2 (id)
DK (2) DK173138B1 (id)
EA (1) EA003278B1 (id)
ES (1) ES2183582T3 (id)
HU (1) HUP0101802A3 (id)
ID (1) ID26997A (id)
NO (1) NO20006021D0 (id)
NZ (1) NZ508225A (id)
PL (1) PL345125A1 (id)
PT (1) PT1123103E (id)
SI (1) SI1123103T1 (id)
SK (1) SK19432000A3 (id)
TR (1) TR200003648T2 (id)
UA (1) UA57140C2 (id)
WO (1) WO2000030657A1 (id)
ZA (1) ZA200006878B (id)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6104802A (en) 1997-02-10 2000-08-15 Genesys Telecommunications Laboratories, Inc. In-band signaling for routing
EP1522318A3 (en) * 1999-04-09 2005-07-06 Advanced Magnetics Incorporated Heat stable coated colloidal iron oxides
PT1169062E (pt) 1999-04-09 2009-12-17 Amag Pharmaceuticals Inc Óxidos de ferro coloidais termoestáveis revestidos
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
PT1973549T (pt) 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
DE102007054794A1 (de) * 2007-11-13 2009-05-14 Agilan Gmbh Wässrige Eisen-Dextran-Zubereitung mit ein oder mehreren Verbindungen der para-Hydroxy-Benzoesäureester und/oder deren Salzen
CN109700828A (zh) 2009-03-25 2019-05-03 法码科思莫斯控股有限公司 稳定的铁寡糖复合物
EP2537866A1 (en) * 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
AU2013351058B2 (en) 2012-11-30 2017-03-16 Pharmacosmos Holding A/S Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation
WO2015150394A1 (en) 2014-04-01 2015-10-08 Pharmacosmos A/S Cryoprotective agent, cryoprotective and cryopreserved compositions, uses thereof, and methods of cryopreservation
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
AU2015342990B2 (en) 2014-11-05 2019-08-29 Nutrition & Biosciences USA 4, Inc. Enzymatically polymerized gelling dextrans
EP3277100B1 (en) 2015-04-03 2023-09-06 Nutrition & Biosciences USA 4, Inc. Oxidized dextran
CA2975289A1 (en) 2015-04-03 2016-10-06 E I Du Pont De Nemours And Company Gelling dextran ethers
WO2018198135A1 (en) 2017-04-26 2018-11-01 Mylan Laboratories Ltd. Improved process for the preparation of iron complex
ES3009466T3 (en) 2017-09-11 2025-03-27 Pharmacosmos Holding As Iron complex compounds for therapeutic use
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普（天津）生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
CN110551019A (zh) * 2019-09-12 2019-12-10 天津医科大学 一种亚铁糖(ⅱ)复合物、制备方法及其应用
CN110804107B (zh) * 2019-09-29 2021-08-31 山东金洋药业有限公司 一种使用右旋糖酐制备右旋糖酐铁水溶液的方法
WO2026017901A1 (en) 2024-07-18 2026-01-22 Malian Biologicals Gmbh Iron supplementation in neurodevelopmental or psychiatric disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK117730A (id)
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
US3549614A (en) * 1967-07-13 1970-12-22 Jan Zbigniew Mioduszewski Method of manufacture of mixed complex compounds of ferric iron with hydrogenated dextran and citric acid or sodium citrate
SU364625A1 (ru) * 1968-07-12 1972-12-28 Способ получения комплексных соединений
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
HU176073B (hu) 1978-03-08 1980-12-28 Chinoin Gyogyszer Es Vegyeszet Eljárás nagy vastartalmú vasdextrán előállítására
US4370476A (en) * 1979-07-17 1983-01-25 Usher Thomas C Dextran polycarboxylic acids, ferric hydroxide complexes
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5075885A (en) * 1988-12-21 1991-12-24 National Semiconductor Corporation Ecl eprom with cmos programming
SU1797196A1 (ru) * 1991-03-29 1996-02-10 Научно-исследовательский ветеринарный институт Нечерноземной зоны РСФСР Препарат для профилактики алиментарной анемии поросят
EP0634174A1 (en) * 1993-07-13 1995-01-18 Takeda Chemical Industries, Ltd. Antianemic composition for veterinary use
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
ATE236196T1 (de) 1995-11-09 2003-04-15 Abbott Lab Verfahren zur herstellung eines kristallinen eisendextrans
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman

Also Published As

Publication number Publication date
EP1123103B1 (en) 2002-10-02
CA2332882A1 (en) 2000-06-02
ZA200006878B (en) 2001-05-10
DE69903329D1 (de) 2002-11-07
DE69903329T2 (de) 2003-07-10
US20030083310A1 (en) 2003-05-01
AU756555B2 (en) 2003-01-16
DK1123103T3 (da) 2002-11-25
PT1123103E (pt) 2003-02-28
EA003278B1 (ru) 2003-04-24
HUP0101802A3 (en) 2003-07-28
AU5027399A (en) 2000-06-13
AR019403A1 (es) 2002-02-20
SK19432000A3 (sk) 2001-06-11
DK173138B1 (da) 2000-02-07
SI1123103T1 (en) 2003-04-30
NO20006021L (no) 2000-11-28
EA200001086A1 (ru) 2001-06-25
HUP0101802A2 (hu) 2001-10-28
DK199801526A (da) 2000-02-07
WO2000030657A1 (en) 2000-06-02
ATE225180T1 (de) 2002-10-15
NZ508225A (en) 2003-10-31
ES2183582T3 (es) 2003-03-16
BR9910834A (pt) 2001-02-13
UA57140C2 (uk) 2003-06-16
EP1123103A1 (en) 2001-08-16
PL345125A1 (en) 2001-12-03
JP2002530345A (ja) 2002-09-17
CN1308539A (zh) 2001-08-15
ID26997A (id) 2001-02-22
TR200003648T2 (tr) 2001-08-21
KR20010071767A (ko) 2001-07-31
US6977249B1 (en) 2005-12-20

Similar Documents

Publication Publication Date Title
NO20006021D0 (no) Fremgangsmåte for fremstilling av jern-dekstran forbindelse
PT1150966E (pt) Metodo de preparacao de 5-cianoftalido
NO20012995D0 (no) Forbindelse nyttige for behandling av inflammatoriske sykdommer
EA200000274A3 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
ID26990A (id) Metode pembuatan dimetilnaftalena
EE200000642A (et) Suurendatud saagisega FAPalfa-spetsiifilised antikehad
ID27092A (id) Pembuatan ftalat anhidrida
IT1315269B1 (it) Metodo per la preparazione di 5-cianoftalide
FI981490A7 (fi) Menetelmä seoslannoitteiden valmistamiseksi
PL342469A1 (en) Method of obtaining stilbenic compounds
NO20010899D0 (no) Forbedring av ugunstige apomorfin-effekter
NO20011083L (no) Krystallinske former av EtOC2--CH2-(R)Cgl-Aze-Pab-OH
NO995851L (no) Fremstillingsfremgangsmåte for isoksasolidinedion forbindelse
PT1082318E (pt) Composto de eter de tia-coroa
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
PT1228056E (pt) Metodo de preparacao de citaloprame
ID16364A (id) Proses pembuatan senyawa multidentat fosfit
NO20020183D0 (no) Fremgangsmåte for deacylering av lipodepsipeptider
FI981975L (fi) Johtuvien häiriöiden suodatuksen optimointi
NO20012099L (no) Fremgangsmåte for fremstilling av 4-arylpiperidin-3- karbinoler og beslektede forbindelser
ID26708A (id) Proses pembuatan kaprolaktam
NO20012811D0 (no) Fremgangsmåte for fremstilling av p-klorfenyl-propanol- derivat
NO20013044D0 (no) Fremgangsmåte for fremstilling av NG-substituerte deaza- adenosinderivater
ID28220A (id) Metode produksi senyawa oksazol

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application